Randomized clinical trial to compare efficacy and safety of repeated courses of rituximab to single-course rituximab followed by maintenance mycophenolate-mofetil in children with steroid dependent nephrotic syndrome

• Verfasst von: Basu, Biswanath [VerfasserIn]
• Verfasst von: Erdmann, Stella [VerfasserIn]
• Verfasst von: Sander, Anja [VerfasserIn]
• Verfasst von: Mahapatra, T. K. S. [VerfasserIn]
• Verfasst von: Schaefer, Franz [VerfasserIn]
• Titel: Randomized clinical trial to compare efficacy and safety of repeated courses of rituximab to single-course rituximab followed by maintenance mycophenolate-mofetil in children with steroid dependent nephrotic syndrome
• Verf.angabe: Biswanath Basu, Stella Preussler, Anja Sander, T.K.S. Mahapatra and Franz Schaefer
• E-Jahr: 2020
• Jahr: 30 November 2020
• Umfang: 11 S.
• Fussnoten: Gesehen am 08.01.2021
• Titel Quelle: Enthalten in: BMC nephrology
• Ort Quelle: London : BioMed Central, 2000
• Jahr Quelle: 2020
• Band/Heft Quelle: 21(2020), Artikel-ID 520, Seite 1-11
• ISSN Quelle: 1471-2369
• DOI: doi:10.1186/s12882-020-02153-5
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Childhood nephrotic syndrome
• Sach-SW: Mycophenolate-Mofetil
• Sach-SW: Rituximab
• Sach-SW: Steroid dependent nephrotic syndrome
• K10plus-PPN: 1744215634
• K10plus-PPN:
  Universitätsbibliothek
• Lokale URL UB: Zum Volltext

Abstract

Approximately 30% of children with idiopathic nephrotic syndrome develop a complicated course with frequent relapses or steroid dependency. Rituximab, a B cell depleting monoclonal antibody, is a safe and effective alternative to steroids or other immunosuppressants for achieving and maintaining remission in this population at short term. Despite the good initial response relapses inevitably occur after regeneration of B lymphocytes, necessitating either repeat courses of rituximab or addition of another steroid-sparing immunosuppressant.